Brain-derived neurotrophic factor gene polymorphism in post-ST-elevation myocardial infarction patients undergoing primary percutaneous intervention

Abstract

Introduction: The goal of this study was to elucidate a link of brain-derived factor (BDNF) Val66Met gene with combined 6-month clinical end points in post-myocardial infarction patients. Methods: 256 post-myocardial infarction patients who underwent primary coronary intervention were enrolled in the study. Variants of Val66Met gene BDNF were identified by real-time chain reaction at baseline. Results: The combined clinical end points (major cardiovascular events and hospitalization) were determined in 61 (23.8%) post-STEMI patients; consequently, 195 (76.2%) patients did not meet the events. linear regression revealed that predictors for combined clinical end points were peak TnI levels, NT-proBNP, SYNTAX score, TIMI score, obesity, left ventricular ejection fraction, and 66ValMet+66MetMet in BDNF gene. The cumulative clinical outcomes (major adverse cardiac events and admission) were determined in 61 (23.8%) patients. Kaplan-Meier curves demonstrated that 66ValVal of BDNF gene was significantly associated with the low number of combined end points. Conclusion: The Val66Met in BDNF gene independently predicted 6-month combined clinical end points in post-myocardial infarction patients.